Last Updated : May 17, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Levemir | Insulin detemir | Diabetes mellitus Type1, Pediatrics | Do not list | Complete | ||
Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Januvia | Sitagliptin phosphate | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
Janumet | Sitagliptin phosphate monohydrate / metformin hydrochloride | Diabetes mellitus (Type 2) | List with clinical criteria and/or conditions | Complete | ||
Onglyza | Saxagliptin | Diabetes mellitus (Type 2) | Do not list | Complete | ||
Synjardy | Empagliflozin and metformin | Diabetes mellitus (Type 2) | Reimburse with clinical criteria and/or conditions | Complete | ||
Entuzity KwikPen | human insulin | Diabetes mellitus | Reimburse with clinical criteria and/or conditions | Complete | ||
Levemir | Insulin detemir | Diabetes mellitus | Withdrawn | |||
Levemir | Insulin detemir | Diabetes mellitus | Do not list | Complete | ||
NovoMix 30 | Insulin aspart/insulin aspart protamine | Diabetes mellitus | Do not list | Complete |